Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography

Table 1

Qualitative data of patients described as poor (, ) and good (, ) responders and in the () and () groups receiving intravitreal bevacizumab treatment. The data were compared using the chi-squared () test. Statistical significance was set at .

			Row			Responders good	Responders poor	Row
Per os treatment
Absent	13	19	32	1.21		21	11	32	0.09
Present	24	21	45			31	14	45
Totals	37	40	77			52	25	77
Insulin
Absent	30	31	61	0.15		41	20	61	0.01
Present	7	9	16			11	5	16
Totals	37	40	77			52	25	77
Gender
Male	15	18	33	0.16		21	12	33	0.40
Female	22	22	44			31	13	44
Totals	37	40	77			52	25	77
Chronic kidney disease
Absent	34	36	70	0.08		46	24	70	1.16
Present	3	4	7			6	1	7
Totals	37	40	77			52	25	77
Hypertension
Absent	13	16	29	0.19		20	9	29	0.04
Present	24	24	48			32	16	48
Totals	37	40	77			52	25	48
Ischemic heart disease
Absent	28	34	62	1.07		45	17	62	3.70
Present	9	6	15			7	8	15
Totals	37	40	77			52	25	77
Myocardial infarction
Absent	33	35	68	0.05		48	20	68	2.48
Present	4	5	9			4	5	9
Totals	37	40	77			52	25	77
Brain stroke
Absent	34	39	73	1.23		50	23	73	0.59
Present	3	1	4			2	2	4
Totals	37	40	77			52	25	77
Lens status (phakic/pseudophakia)
Phakic	24	25	49	0.05		31	18	49	1.12
Pseudophakia	13	15	28			21	7	28
Totals	37	40	77			52	25	77
Laterality
OD	19	23	42	0.29		25	17	42	2.70
OS	18	17	35			27	8	35
Totals	37	40	77			52	25	77
Combined treatment
Absent	31	30	61	0.90		42	19	61	0.23
Present	6	10	16			10	6	16
	37	40	77			52	25	77